{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-084156","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.213098+00:00","generated_at":"2026-05-15T22:37:23.108558+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Apellis adds Dr. Mikael Dolsten as independent Class I director","bullets":["Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.","Dolsten deemed independent under Nasdaq rules; no committee appointments at this time.","Received initial equity grant: option with $300,000 Black-Scholes value (3-year vest) and RSUs worth $300,000 (1-year cliff vest).","Standard indemnification agreement in place; no family relationships or transactions with the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-084156","json":"https://secwatch.observer/filing/0001193125-26-084156.json","markdown":"https://secwatch.observer/filing/0001193125-26-084156.md","text":"https://secwatch.observer/filing/0001193125-26-084156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526084156/0001193125-26-084156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312526084156/d115780d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:37:23.108558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}